Stay updated with breaking news from Patrick Chaltin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven,...
GuruFocus Article or News written by PRNewswire and the topic is about:
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain - read this article along with other careers information, tips and advice on BioSpace
Researchers have developed a potent inhibitor of the dengue virus, which causes roughly 100 million cases of symptomatic cases of dengue fever annually.
Researchers at the KU Leuven Rega Institute and CD3 have developed an ultrapotent inhibitor of the dengue virus, which causes the tropical disease known as dengue. The teams collaborated closely with Janssen Pharmaceutica, N.V. The antiviral molecule is exceptionally effective against all known dengue variants and could be used for therapeutic and prevention purposes. The teams have published their findings in Nature.